Shares of SI-BONE, Inc. (SIBN) surged 5.96% in pre-market trading on Tuesday, following the release of the company's impressive first-quarter 2025 financial results. The medical device maker, known for its minimally invasive surgical devices for the sacroiliac joint, outperformed Wall Street expectations on both earnings and revenue fronts.

SI-BONE reported a quarterly adjusted loss of $0.15 per share, significantly better than the average analyst estimate of a $0.23 loss per share. The company's revenue soared 24.9% year-over-year to $47.29 million, surpassing the Street forecast of $45.17 million. This marks the fourth consecutive quarter that SI-BONE has beaten earnings estimates, demonstrating consistent operational improvement.

The strong quarterly performance has bolstered investor confidence in SI-BONE's growth trajectory. Citizens JMP analyst David Turkaly reiterated a Buy rating on the stock with a price target of $32.00, suggesting substantial upside potential. The current average analyst rating on SI-BONE shares is "buy," with 9 out of 9 analysts recommending either "strong buy" or "buy." Wall Street's median 12-month price target for the stock stands at $24.50, further supporting the bullish sentiment surrounding the company's prospects in the medical equipment and supplies sector.